Publicaciones en las que colabora con ANTONIO ESPINOSA UBEDA (22)

2009

  1. Acyclonucleosides, modified seco-nucleosides, and salicyl- or catechol-derived acyclic 5-fluorouracil O,N-acetals: Antiproliferative activities, cellular differentiation and apoptosis

    Current Medicinal Chemistry, Vol. 16, Núm. 9, pp. 1166-1183

2008

  1. Anticancer activity of (1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl)-pyrimidines and -purines against the MCF-7 cell line: Preliminary cDNA microarray studies

    Bioorganic and Medicinal Chemistry Letters, Vol. 18, Núm. 4, pp. 1457-1460

  2. Regiospecific microwave-assisted synthesis and cytotoxic activity against human breast cancer cells of (RS)-6-substituted-7- or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or -9H-purines

    European Journal of Medicinal Chemistry, Vol. 43, Núm. 8, pp. 1742-1748

  3. Synthesis and anticancer activity of (R,S)-9-(2,3-dihydro-1,4-benzoxathiin- 3-ylmethyl)-9H-purines

    ChemMedChem, Vol. 3, Núm. 1, pp. 127-135

2007

  1. 5-fluorouracil derivatives induce differentiation mediated by tubulin and HLA class I modulation

    Medicinal Chemistry, Vol. 3, Núm. 3, pp. 233-239

  2. 6′-Chloro-7- or 9-(2,3-dihydro-5H-4,1-benzoxathiepin-3-yl)-7H- or 9H-purines and their corresponding sulfones as a new family of cytotoxic drugs

    Tetrahedron, Vol. 63, Núm. 1, pp. 183-190

  3. A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells

    Breast Cancer Research and Treatment, Vol. 105, Núm. 3, pp. 237-246

  4. Antiproliferative activity, cell-cycle dysregulation, and cellular differentiation: Salicyl- and catechol-derived acyclic 5-fluorouracil O,N-acetals against breast cancer cells

    ChemMedChem, Vol. 2, Núm. 12, pp. 1814-1821

2006

  1. Synthesis and anticancer activity studies of novel 1-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)uracil and (6′-substituted)-7- or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or 9H-purines

    Tetrahedron, Vol. 62, Núm. 50, pp. 11724-11733

2005

  1. Antitumoural properties of benzannelated seven-membered 5-fluorouracil derivatives and related open analogues. Molecular markers for apoptosis and cell cycle dysregulation

    Farmaco

  2. New medium oxacyclic O,N-acetals and related open analogues: Biological activities

    Current Medicinal Chemistry, Vol. 12, Núm. 12, pp. 1423-1438

  3. Synthesis of novel 1-(2,3-dihydro-5H-4,1-benzoxathiepin-3-yl)-uracil and -thymine, and their corresponding S-oxidized derivatives

    Tetrahedron, Vol. 61, Núm. 43, pp. 10363-10369

2004

  1. Actual targets in cytodifferentiation cancer therapy

    Current Topics in Medicinal Chemistry, Vol. 4, Núm. 2, pp. 175-202

  2. Growth inhibition, G 1-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives

    Investigational New Drugs, Vol. 22, Núm. 4, pp. 379-389

  3. Synthesis of tetrahydrobenzoxazepine acetals with electron-withdrawing groups on the nitrogen atom. Novel scaffolds endowed with anticancer activity against breast cancer cells

    Tetrahedron, Vol. 60, Núm. 50, pp. 11547-11557

2003

  1. Medium benzene-fused oxacycles with the 5-fluorouracil moiety: Synthesis, antiproliferative activities and apoptosis induction in breast cancer cells

    Tetrahedron, Vol. 59, Núm. 29, pp. 5457-5467

  2. Neighbouring-group participation as the key step in the reactivity of acyclic and cyclic salicyl-derived O,O-acetals with 5-fluorouracil. Antiproliferative activity, cell cycle dysregulation and apoptotic induction of new O,N-acetals against breast cancer cells

    Tetrahedron, Vol. 59, Núm. 40, pp. 8017-8026

  3. Synthesis and evaluation of new 5-fluorouracil antitumor cell differentiating derivatives

    Bioorganic and Medicinal Chemistry, Vol. 11, Núm. 3, pp. 315-323

2000

  1. Modulation of myogenic differentiation in a human rhabdomyosarcoma cell line by a new derivative of 5-fluorouracil (QF-3602)

    Japanese Journal of Cancer Research, Vol. 91, Núm. 9, pp. 934-940

1999

  1. GR-891: A novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells

    British Journal of Cancer, Vol. 79, Núm. 5-6, pp. 807-813